Life science consulting company m-Squared Consulting S.r.L on Tuesday reported the first positive signal from EMA's Pandemic Task Force in the Rapid Scientific Advice procedure for the drug cyclobenzaprine as one of the most promising treatments for COVID-19.
The company said cyclobenzaprine is used for the treatment of acute musculoskeletal conditions and the drug is now been repositioned as anti-COVID-19 therapy.
Based on preclinical scientific evidence, cyclobenzaprine has been shown to inhibit viral replication by interfering in at least two steps of the infection process , entry and replication, and to represent a novel therapeutic solution for the treatment of COVID-19.
According to the company, the mechanism of action intervenes in the infection process and the molecule has the ability to reach the central nervous system, allowing the development of an effective therapy for Neuro-Covid symptoms. Efficacy against variants will have to be verified.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials